Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells.
Samuelsson
Jan
J
Mutschler
Manuel
M
Birgegård
Gunnar
G
Gram-Hansen
Poul
P
Björkholm
Magnus
M
Pahl
Heike L
HL
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D053614:Janus Kinase 2; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D011087:Polycythemia Vera / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D011092:Polyethylene Glycols; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D011994:Recombinant Proteins; D013920:Thrombocythemia, Essential / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011518:Proto-Oncogene Proteins; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D011505:Protein-Tyrosine Kinases; C507924:JAK2 protein, human; D053614:Janus Kinase 2; C417083:peginterferon alfa-2b